New program aims to keep cancer patients on treatment by spotting side effects sooner
NCT ID NCT06693687
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This study tests the ApricityCare program, which helps people with metastatic cancer and their doctors spot treatment side effects early. The goal is to manage these side effects quickly so patients can stay on their cancer therapy longer. About 425 adults starting systemic cancer therapy will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ApricityCare program (behavioral intervention for early detection and management of treatment side effects)
What this could lead to
If it works, this could help people with metastatic cancer stay on their treatment longer by catching and managing side effects early.
What could go wrong
This is an early study without a control group, so it's unclear if the program truly reduces treatment stops. Results may not apply to all cancer types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.